Tumor targeting using liposomal antineoplastic drugs

International Journal of Nanomedicine

Volumn 3, Issue 1, 2008, Pages 21-29

  Huwyler, Jörg ^a   Drewe, Jürgen ^b   Krähenbühl, Stephan ^b  

^a UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Antineoplastic drugs; Immunoliposomes; Liposomes; Pegylation; Steric stabilization; Tumor targeting

Indexed keywords

ANTHRACENE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CISPLATIN; COLCHICINE; CYTARABINE; CYTOKINE; DACTINOMYCIN; DAUNORUBICIN; DIGOXIN; DOXORUBICIN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLIC ACID; IMMUNOMODULATING AGENT; LIPOPLATIN; LIPOSOME; MONOCLONAL ANTIBODY; RICIN A; RITONAVIR; SHORT HAIRPIN RNA; TOPOTECAN; TRANSFERRIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BRAIN CANCER; BREAST CANCER; CANCER GENE THERAPY; CANCER INHIBITION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG TRANSPORT; ENZYME DEGRADATION; EPITHELIUM TUMOR; GENE SILENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LIPOSOMAL DELIVERY; LYMPHOMA; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; REVIEW; RNA INTERFERENCE; TUMOR;

ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPOSOMES; NEOPLASMS;

EID: 61649093243     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Advani R, Saba HI, Tallman MS, et al. 1999. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood, 93:787-95.
2. Allen TM. 1994. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci, 15:215-20.
3. Allen TM, Brandeis E, Hansen CB, et al. 1995. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta, 1237:99-108.
4. Allen TM, Chonn A. 1987. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett, 223:42-6.
5. Anabousi S, Bakowsky U, Schneider M, et al. 2006. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci, 29:367-74.
6. Bailey AL. 1994. Antibody-directed enzyme prodrug therapy (Adept). J Control Release, 28:187-93.
7. Baselga J. 2000. Clinical trials of single-agent trastuzumab (Herceptin). Semin Oncol, 27:20-6.
8. Blume G, Cevc G, Crommelin MD, et al. 1993. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta, 1149:180-4.
9. Boesch D, Gavériaux C, Jachez B, et al. 1991. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res, 51:4226-33.
10. Cerletti A, Drewe J, Fricker G, et al. 2000. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J Drug Targeting, 8:435-47.
11. Connor J, Huang L. 1986. pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res, 46:3431-5.
12. Daemen T. 1992. Activation of Kupffer cell tumoricidal activity by immunomodulators encapsulated in liposomes. Res Immunol, 143:211-4.
13. Daemen T, Hofstede G, Ten Kate MT, et al. 1995. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer, 61:716-21.
14. Derycke A, Kamuhabwa A, Gijsens A, et al. 2004. Transferrin-conjugated liposome targeting of the photosensitizer A1PcS4 to rat bladder carcinoma cells. Journal of the National Cancer Institute, 96:1620-30.
15. Drummond DC, Zignani M, Leroux J. 2000. Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res, 39:409-60.
16. Efferth T, Osieka R. 1993. Clinical relevance of the MDR-1 gene and its gene product, P-glycoprotein, for cancer chemotherapy: a meta-analysis. Tumordiagn u Ther, 14:238-43.
17. Ewer MS, Martin FJ, Henderson C, et al. 2004. Cardiac safety of liposomal anthracyclines. Semin Oncol, 31:161-81.
18. Flynn JM, Byrd JC. 2000. Campath-1H monoclonal antibody therapy. Curr Opin Oncol, 12:574-81.
19. Fonseca MJ, Jagtenberg JC, Haisma HJ, et al. 2003. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of pro-drugs: comparison with the corresponding antibody-enzyme conjugate. Pharm Res, 20:423-8.
20. Frank MM. 1993. The reticuloendothelial system and bloodstream clearance. J Lab Clin Med, 122:487-8.
21. Friden PM, Walus LR, Musso GF, et al. 1991. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA, 88:4771-5.
22. Gabizon A, Catane R, Uziely B, et al. 1994. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res, 54:987-92.
23. Gabizon A, Papahadjopoulos D. 1992. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta, 1103:94-100.
24. Gabizon A, Shmeeda H, Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet, 42:419-36.
25. Gabizon A, Shmeeda H, Horowitz AT, et al. 2004. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev, 56:1177-92.
26. Gabizon AA. 2001. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest, 19:424-36.
27. Gabizon AA, Shmeeda H, Zalipsky S. 2006. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res, 16:175-83.
28. Gijsen A, Derycke A, Missiaen L, et al. 2002. Targeting of the phototoxic compound AIPcS4 to HeLa cells by transferrin conjugated PEG-liposomes. Int J Cancer, 101:78-85.
29. Gosselin MA, Lee RJ. 2002. Folate receptor-targeted liposomes as vectors for therapeutic agents. Biotechnol Annu Rev, 8:103-31.
30. Gulati M, Bajad S, Singh S, et al. 1998. Development of liposomal amphotericin B formulation. J Microencapsul, 15:137-51.
31. Hamilton A, Biganzoli L, Coleman R, et al. 2002. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with meta-static breast cancer. European Organization for Research and Treatment of Cancer. Ann Oncol, 13:910-8.
32. Hansen CB, Kao GY, Moase EH, et al. 1995. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta, 1239:133-44.
33. Hilgenbrink AR, Low PS. 2005. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci, 94:2135-46.
34. Hofheinz RD, Gnad-Vogt SU, Beyer U, et al. 2005. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs, 16:691-707.
35. Hosokawa S, Tagawa T, Niki H, et al. 2003. Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner. Br J Cancer, 89:1545-51.
36. Huwyler J, Cerletti A, Fricker G, et al. 2002. By-passing of P-glycoprotein using immunoliposomes. J Drug Targeting, 10:73-9.
37. Huwyler J, Wu D, Pardridge WM. 1996. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA, 93:14164-9.
38. Imai K, Takaoka A. 2006. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer, 6:714-27.
39. Ishida O, Maruyama K, Tanahashi H, et al. 2001. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res, 18:1042-8.
40. Ito A, Shinkai M, Honda H, et al. 2005. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng, 100:1-11.
41. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455:152-62.
42. Juliano RL, Stamp D. 1978. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Bioch Pharmacol, 27:21-7.
43. Kanwar YS, Liu ZZ, Kashihara N, et al. 1991. Current status of the structural and functional basis of glomerular filtration and proteinuria. Semin Nephrol, 11:390-413.
44. Kirpotin D, Park JW, Hong K, et al. 1997. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry, 36:66-75.
45. Klein I, Sarkadi B, Varadi A. 1999. An inventory of the human ABC proteins. Biochim Biophys Acta, 1461:237-62.
46. Klibanov AL, Maruyama K, Torchilin VP, et al. 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett, 268:235-7.
47. Krishna R, Mayer LD. 1999. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR). Anticancer Res, 19:2885-91.
48. Lasic DD. 1996. Doxorubicin in sterically stabilized liposomes. Nature, 380:561-2.
49. Lasic DD, Papahadjopoulos D. 1995. Liposomes revisited. Science, 267:1275-6.
50. Lemaire M, Bruelisauer A, Guntz P, et al. 1996. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol, 38:481-6.
51. Litman T, Druley TE, Stein WD, et al. 2001. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci, 58:931-59.
52. Liu Y, Liggitt D, Zhong W, et al. 1995. Cationic liposome-mediated intravenous gene delivery. J Biol Chem, 270:24864-70.
53. Liu Y, Mounkes LC, Liggitt HD, et al. 1997. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol, 15:167-73.
54. Lobo ED, Hansen RJ, Balthasar JP. 2004. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci, 93:2645-68.
55. Maeda H. 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul, 41:189-207.
56. Maeda H, Wu J, Sawa T, et al. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65:271-84.
57. Mamot C, Drummond DC, Hong K, et al. 2003. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updates, 6:271-9.
58. Mastrobattista E, Koning GA, Storm G. 1999. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev, 40:103-27.
59. Matsumura Y, Gotoh M, Muro K, et al. 2004. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol, 15:517-25.
60. Matsuo H, Wakasugi M, Takanaga H, et al. 2001. Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein. J Control Release, 77:77-86.
61. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol, 16:2825-33.
62. Mizuno N, Sugiyama Y. 2002. Drug transporters: their role and importance in the selection and development of new drugs. Drug Metab Pharmacokinet, 17:93-108.
63. Moghimi SM, Patel HM. 1992. Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells. Biochim Biophys Acta, 1135:269-74.
64. Mross K, Niemann B, Massing U, et al. 2004. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol, 54:514-5124.
65. Osaka G, Carey K, Cuthbertson A, et al. 1996. Pharmacokinetics, tissue distribution, and expression efficiency of plasmid [33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach. J Pharm Sci, 85:612-8.
66. Pan XQ, Lee RJ. 2005. In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model. Anticancer Res, 25:343-6.
67. Papahadjopoulos D, Allen TM, Gabizon A, et al. 1991. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA, 88:11460-4.
68. Pardridge WM. 1993. Brain drug delivery and blood-brain barrier transport. Drug Delivery, 1:83-101.
69. Park JW, Benz CC, Martin FJ. 2004. Future directions of liposome-and immunoliposome-based cancer therapeutics. Semin Oncol, 31:196-205.
70. Park JW, Hong K, Kirpotin DB, et al. 2002. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res, 8:1172-81.
71. Park JW, Kirpotin DB, Hong K, et al. 2001. Tumor targeting using anti-her2 immunoliposomes. J Control Release, 74:95-113.
72. Pastan II, Kreitman RJ. 1998. Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev, 31:53-88.
73. Photos PJ, Bacakova L, Discher B, et al. 2003. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release, 90:323-34.
74. Rädler JO, Koltover I, Salditt T, et al. 1997. Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science, 275:810-4.
75. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev, 55:3-29.
76. Schnell R, Borchmann P, Staak JO, et al. 2003. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol, 14:729-36.
77. Schnyder A, Huwyler J. 2005. Drug transport to brain with targeted liposomes. NeuroRx, 2:99-107.
78. Shahinian S, Silvius JR. 1995. A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes. Biochim Biophys Acta, 1239:157-67.
79. Shi N, Pardridge WM. 2000. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA, 97:7567-72.
80. Shmeeda H, Mak L, Tzemach D, et al. 2006. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther, 5:818-24.
81. Sikic BI. 1997. Pharmacologic approaches to reversing multidrug resistance. Semin Hematol, 34:40-7.
82. Sinkule JA, Rosen ST, Radosevich JA. 1991. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods. Tumour Biol, 12:198-206.
83. Skarlatos S, Yoshikawa T, Pardridge WM. 1995. Transpoit of [125I]transferrin through the rat blood-brain barrier. Brain Res, 683:164-71.
84. Song S, Suzuki H, Kawai R, et al. 1999. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos, 27:689-94.
85. Spector MS, Schnur JM. 1997. DNA ordering on a lipid membrane. Science, 275:791-2.
86. Stathopoulos GP, Boulikas T, Vougiouka M, et al. 2005. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep, 13:589-95.
87. Stevens PJ, Lee RJ. 2003. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes. Anticancer Res, 23:439-42.
88. Suzuki S, Inoue K, Hongoh A, et al. 1997. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor. Br J Cancer, 76:83-9.
89. Thiebaut F, Tsuruo T, Hamada H, et al. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissue. Proc Natl Acad Sci, 84:7735-8.
90. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 4:145-60.
91. Uster PS, Allen TM, Daniel BE, et al. 1996. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett, 386:243-6.
92. Vingerhoeds MH, Haisma HJ, van MM, et al. 1993. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs. FEBS Letters, 336:485-90.
93. Vingerhoeds MH, Steerenberg PA, Hendriks JJ, et al. 1996. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br J Cancer, 74:1023-9.
94. Wang S, Low PS. 1998. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J Control Release, 53:39-48.
95. Waterhouse DN, Tardi PG, Mayer LD, et al. 2001. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf, 24:903-20.
96. Wong JY, Kuhl TL, Israelachvili JN, et al. 1997. Direct measurement of a tethered ligand-receptor interaction potential. Science, 275:820-2.
97. Woodle MC, Matthay KK, Newman MS, et al. 1992. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta, 1105:193-200.
98. Worth LL, Jia SF, An T, et al. 1999. ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunol Immunother, 48:312-20.
99. Xu L, Huang CC, Huang W, et al. 2002. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther, 1:337-46.
100. Yuan F, Dellian M, Fukumura D, et al. 1995. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res, 55:3752-6.
101. Zhang Y, Calon F, Zhu C, et al. 2003. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther, 14:1-12.
102. Zhang Y, Schlachetzki F, Pardridge WM. 2003. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther, 7:11-8.